NCT05720455View on ClinicalTrials.gov

Study to Assess Safety and Efficacy of Fexofenadine Hydrochloride (HCL) + Pseudoephedrine HCL Fixed Dose Combination in Indian Male and Female Participants With Allergic Rhinitis (AR) Who Are 12 Years and Above

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

203

Participants

Timeline

Start Date

June 6, 2025

Primary Completion Date

October 30, 2025

Study Completion Date

October 30, 2025

Conditions
Rhinitis Allergic
Interventions
DRUG

Fexofenadine HCL and pseudoephedrine HCL

Extended-Release Tablets

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT05720455 - Study to Assess Safety and Efficacy of Fexofenadine Hydrochloride (HCL) + Pseudoephedrine HCL Fixed Dose Combination in Indian Male and Female Participants With Allergic Rhinitis (AR) Who Are 12 Years and Above | Biotech Hunter | Biotech Hunter